FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028553713> ?p ?o ?g. }

• W2028553713 endingPage "683" @default.
• W2028553713 startingPage "677" @default.
• W2028553713 abstract "Objective To evaluate, from a societal perspective, the cost-effectiveness of adding bevacizumab to first-line therapy based on outcomes from the GOG-218 and ICON-7 trials. Methods A three-state Markov model was used. The time horizon was until the death of 99% of the initial cohort of 1000 individuals. Costs and quality-adjusted life-years (QALYs) were discounted at an annual rate of 3%. All costs were adjusted to 2013 USD. The incremental cost-effectiveness ratio (ICER) was reported as incremental cost per QALY gained. The robustness of the result was checked with one-way sensitivity analyses and for relevant clinical situations (i.e. varying the drug of choice to treat cancer recurrence). Subgroup analysis was conducted to identify subgroup of population for whom the strategy could be cost-effective. The potential impact of biosimilar bevacizumab was considered, using a 30% price reduction. Results For the GOG-218 study protocol, widely followed in US, the addition of bevacizumab results in an ICER of $2,420,691/QALY. For the ICON-7 study protocol, the ICER is $225,515/QALY. The results of the model were sensitive to the quality of life (QoL) and the median progression free survival (PFS). Biosimilar bevacizumab didn't reduce cost sufficiently to change conclusions. First-line augmentation is cost-effective, with biosimilar bevacizumab, for stage IV patients ($126,169/QALY), ECOG PS1 patients ($116,575/QALY) and for patients with suboptimal residual disease ($122,822/QALY) as per the ICON-7 protocol. Conclusion Addition of bevacizumab, by in large, is cost-ineffective. It can become cost-effective with the ICON-7 protocol, in patients at high risk of progression using biosimilar bevacizumab." @default.
• W2028553713 created "2016-06-24" @default.
• W2028553713 creator A5062455117 @default.
• W2028553713 creator A5080378534 @default.
• W2028553713 date "2014-03-01" @default.
• W2028553713 modified "2023-09-28" @default.
• W2028553713 title "Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer" @default.
• W2028553713 cites W1537880623 @default.
• W2028553713 cites W1610065887 @default.
• W2028553713 cites W1904695471 @default.
• W2028553713 cites W1960327677 @default.
• W2028553713 cites W1966754084 @default.
• W2028553713 cites W1997514259 @default.
• W2028553713 cites W2008677216 @default.
• W2028553713 cites W2023543859 @default.
• W2028553713 cites W2029630138 @default.
• W2028553713 cites W2031456603 @default.
• W2028553713 cites W2031682298 @default.
• W2028553713 cites W2052521108 @default.
• W2028553713 cites W2061853769 @default.
• W2028553713 cites W2076494316 @default.
• W2028553713 cites W2103799380 @default.
• W2028553713 cites W2113122060 @default.
• W2028553713 cites W2116183806 @default.
• W2028553713 cites W2130659077 @default.
• W2028553713 cites W2130941707 @default.
• W2028553713 cites W2135947389 @default.
• W2028553713 cites W2148199952 @default.
• W2028553713 cites W2149198543 @default.
• W2028553713 cites W2151050516 @default.
• W2028553713 cites W2154175915 @default.
• W2028553713 cites W2163012374 @default.
• W2028553713 cites W2168943084 @default.
• W2028553713 cites W2169962529 @default.
• W2028553713 cites W2293035635 @default.
• W2028553713 cites W2333245858 @default.
• W2028553713 cites W4233920089 @default.
• W2028553713 doi "https://doi.org/10.1016/j.ygyno.2014.01.021" @default.
• W2028553713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24463160" @default.
• W2028553713 hasPublicationYear "2014" @default.
• W2028553713 type Work @default.
• W2028553713 sameAs 2028553713 @default.
• W2028553713 citedByCount "26" @default.
• W2028553713 countsByYear W20285537132014 @default.
• W2028553713 countsByYear W20285537132015 @default.
• W2028553713 countsByYear W20285537132016 @default.
• W2028553713 countsByYear W20285537132017 @default.
• W2028553713 countsByYear W20285537132018 @default.
• W2028553713 countsByYear W20285537132019 @default.
• W2028553713 countsByYear W20285537132020 @default.
• W2028553713 countsByYear W20285537132021 @default.
• W2028553713 countsByYear W20285537132022 @default.
• W2028553713 countsByYear W20285537132023 @default.
• W2028553713 crossrefType "journal-article" @default.
• W2028553713 hasAuthorship W2028553713A5062455117 @default.
• W2028553713 hasAuthorship W2028553713A5080378534 @default.
• W2028553713 hasConcept C112930515 @default.
• W2028553713 hasConcept C126322002 @default.
• W2028553713 hasConcept C141071460 @default.
• W2028553713 hasConcept C143998085 @default.
• W2028553713 hasConcept C2776694085 @default.
• W2028553713 hasConcept C2777802072 @default.
• W2028553713 hasConcept C2908647359 @default.
• W2028553713 hasConcept C3019080777 @default.
• W2028553713 hasConcept C59491497 @default.
• W2028553713 hasConcept C64332521 @default.
• W2028553713 hasConcept C71924100 @default.
• W2028553713 hasConcept C99454951 @default.
• W2028553713 hasConceptScore W2028553713C112930515 @default.
• W2028553713 hasConceptScore W2028553713C126322002 @default.
• W2028553713 hasConceptScore W2028553713C141071460 @default.
• W2028553713 hasConceptScore W2028553713C143998085 @default.
• W2028553713 hasConceptScore W2028553713C2776694085 @default.
• W2028553713 hasConceptScore W2028553713C2777802072 @default.
• W2028553713 hasConceptScore W2028553713C2908647359 @default.
• W2028553713 hasConceptScore W2028553713C3019080777 @default.
• W2028553713 hasConceptScore W2028553713C59491497 @default.
• W2028553713 hasConceptScore W2028553713C64332521 @default.
• W2028553713 hasConceptScore W2028553713C71924100 @default.
• W2028553713 hasConceptScore W2028553713C99454951 @default.
• W2028553713 hasIssue "3" @default.
• W2028553713 hasLocation W20285537131 @default.
• W2028553713 hasLocation W20285537132 @default.
• W2028553713 hasOpenAccess W2028553713 @default.
• W2028553713 hasPrimaryLocation W20285537131 @default.
• W2028553713 hasRelatedWork W2028553713 @default.
• W2028553713 hasRelatedWork W2130320283 @default.
• W2028553713 hasRelatedWork W2899615166 @default.
• W2028553713 hasRelatedWork W2922020001 @default.
• W2028553713 hasRelatedWork W3041411269 @default.
• W2028553713 hasRelatedWork W3158593454 @default.
• W2028553713 hasRelatedWork W4210934974 @default.
• W2028553713 hasRelatedWork W4224223079 @default.
• W2028553713 hasRelatedWork W4307028136 @default.
• W2028553713 hasRelatedWork W4309218607 @default.
• W2028553713 hasVolume "132" @default.
• W2028553713 isParatext "false" @default.
• W2028553713 isRetracted "false" @default.

• next